key: cord-0284391-5w73dnka authors: Bruxvoort, K.; Sy, L. S.; Qian, L.; Ackerson, B. K.; Luo, Y.; Lee, G. S.; Tian, Y.; Florea, A.; Aragones, M.; Tubert, J. E.; Takhar, H. S.; Ku, J. H.; Paila, Y. D.; Talarico, C. A.; Tseng, H. F. title: Effectiveness of mRNA-1273 against Delta, Mu, and other emerging variants date: 2021-10-01 journal: nan DOI: 10.1101/2021.09.29.21264199 sha: c7ce5cd52967a969465614c8b40f268dee487e38 doc_id: 284391 cord_uid: 5w73dnka Background: Real-world studies have found high vaccine effectiveness (VE) of mRNA-based COVID-19 vaccines, but reduced VE against the Delta variant and waning protection have been reported, with few studies examining mRNA-1273 variant-specific VE. Methods: We conducted a test-negative case-control study at Kaiser Permanente Southern California. Whole genome sequencing was conducted for SARS-CoV-2 positive specimens collected from 3/1/2021 to 7/27/2021. Test-positive cases were matched 1:5 to test-negative controls on age, sex, race/ethnicity, and specimen collection date. Outcomes included SARS-CoV-2 infection and hospitalization. Exposures were 2 doses or 1 dose of mRNA-1273 [≥]14 days prior to specimen collection versus no COVID-19 vaccination. Conditional logistic regression was used to compare odds of vaccination among cases versus controls, adjusting for confounders. VE was calculated as (1-odds ratio)x100%. Results: The study included 8,153 cases and their matched controls. Two-dose VE (95% confidence interval) was 86.7% (84.3-88.7%) against Delta infection, 98.4% (96.9-99.1%) against Alpha, 90.4% (73.9-96.5%) against Mu, 96-98% against other identified variants, and 79.9% (76.9-82.5%) against unidentified variants. VE against Delta declined from 94.1% (90.5-96.3%) 14-60 days after vaccination to 80.0% (70.2-86.6%) 151-180 days after vaccination. Waning was less pronounced for non-Delta variants. VE against Delta was lower among individuals aged [≥]65 years (75.2% [59.6-84.8%]) than those aged 18-64 years (87.9% [85.5-89.9%]). VE against Delta hospitalization was 97.6% (92.8-99.2%). One-dose VE was 77.0% (60.7-86.5%) against Delta infection. Conclusions: Two doses of mRNA-1273 were highly effective against all SARS-CoV-2 variants. However, VE against Delta moderately declined with increasing time since vaccination. variants was 100% and 96.4%, respectively. 11 A study in Canada found VE of mRNA-based vaccines against Alpha and Beta/Gamma (P.1) infection of 90% and 88%, respectively. 12 However, as Delta became predominant, concerns arose that mRNA-based vaccines could be less effective. 13, 14 The higher transmissibility of Delta led to a surge in infections, hospitalizations, and deaths in the US. 15 These cases have occurred overwhelmingly among unvaccinated individuals but have also included breakthrough cases. 16, 17 Although studies have found sustained VE of mRNA-based vaccines against COVID-19 hospitalization during periods overlapping with or during the Delta surge, [18] [19] [20] Molecular diagnostic testing for SARS-CoV-2 is widely available at KPSC for symptomatic and asymptomatic individuals and is required prior to procedures or hospital admission. Specimens are primarily collected using nasopharyngeal/oropharyngeal swabs or saliva (asymptomatic individuals only) and tested using the RT-PCR TaqPath™ COVID-19 High-Throughput Combo Kit The study used a test-negative design to examine VE of mRNA-1273 against SARS-CoV-2 variants. Individuals who had a SARS-CoV-2 positive test sent for WGS or a negative test from March 1, 2021 to July 27, 2021 were eligible for inclusion in the study if they were age ≥18 years and had ≥12 months of KPSC membership as of the specimen collection date. Individuals were excluded if they received a COVID-19 vaccine other than mRNA-1273, received 2 doses of mRNA-1273 <24 days apart or <14 days prior to specimen collection date, received >2 doses of mRNA-1273 prior to the specimen collection date, or had a positive SARS-CoV-2 test or COVID- (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101/2021.09.29.21264199 doi: medRxiv preprint diagnosis code) from March 1, 2020 to specimen collection date, and immunocompromised status. The distribution of variants was described by vaccination status and by calendar time. Characteristics of cases and controls for each analysis were described and compared using the χ 2 test or Fisher's exact test for categorical variables and the two-sample t-test or Wilcoxon rank-sum test for continuous variables. Conditional logistic regression was used to estimate the odds ratios (OR) and 95% confidence interval (95% CI) for vaccination, comparing cases and controls. Analyses were adjusted for potential confounders, determined by absolute Analyses of VE by time since receipt of second dose of mRNA-1273 (14-60 days, 61-90 days, 91-120 days, 121-150 days, 151-180 days, and >180 days) were conducted for Delta (overall and by age), non-Delta variants, and unidentified variants. All analyses were conducted using SAS software version 9.4 (Cary, USA). The study included 8,153 test-positive cases, with variants identified for 5,186 cases (63.6% overall, of which 39.4% were Delta, 27.7% Alpha, 11.4% Epsilon, 6.9% Gamma, 2.2% Iota, 1.4% Mu, and 11.1% Other) ( Table 1 and Figures S1-2) . Among fully vaccinated cases, 85.0% of identified variants were Delta. Approximately 36% of specimens failed WGS. Compared to successfully sequenced specimens, specimens that failed sequencing were more often from All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. physician/employee status. Compared to controls, Delta cases had lower comorbidity and frailty indices and less commonly had kidney disease, heart disease, liver disease, diabetes, immunocompromised status, pregnancy, and history of COVID-19 diagnosis, but more commonly had history of SARS-CoV-2 molecular testing and Medicaid. Delta cases also had fewer health care visits in the prior year than controls, and less commonly had preventive care. In addition, there were some differences by medical center, month of specimen collection, and specimen type. Characteristics of cases and matched controls for non-Delta and unidentified variants are described in Tables S2-S8 . Among Delta cases, 232 (11.4%) were fully vaccinated ( Figure 1 and (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Figure S3 ). Among those aged 18-64 years, VE against Delta declined from 95.1% (91. .1%) at 14-60 days to 79.4% (68. .3%) at 151-180 days. Among individuals aged ≥65 years, confidence intervals were wide due to fewer cases in this age group, making trends less apparent. However, during the study period robust protection was observed against hospitalization for Delta. Among hospitalized Delta cases and controls, 5 (3.5%) and 4,815 (40.1%) were fully vaccinated, respectively ( Table 3) . VE against hospitalization for Delta was high at 97.6% (92.8-99.2%). Similarly, VE against hospitalization for unidentified variants was 96.6% (89.4-98.9%). All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 13, 30 During the Delta phase of the pandemic, breakthrough infections among fully vaccinated individuals have occurred, 16 17 but VE of COVID-19 vaccines against severe disease has remained robust. 18, 19, 31, 34 In our study, VE against hospitalization with Delta was high (97.6%). Only 5 fully vaccinated Delta cases were hospitalized, no fully vaccinated non-Delta cases were hospitalized, and no hospitalized deaths occurred among any fully vaccinated cases. This finding is consistent with prior studies suggesting that fully vaccinated individuals with breakthrough infections tend to have attenuated viral load, fewer symptoms, and shorter illness duration, though severe outcomes can still occur. 7, 35, 36 In this study, variants were unidentified for the substantial proportion of specimens that failed sequencing, possibly due to lower viral loads, timing of specimen collection relative to symptom onset, or poor specimen quality. The higher proportion of failed vs. successfully sequenced All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 20, 21, 29, 32 We also identified a decline in VE of mRNA-1273 against non-Delta infections but this reduction was less pronounced than for Delta or for unidentified variants. Declines in VE might also be partly due to differences in characteristics and behaviors of individuals vaccinated earlier vs. later in phased vaccine rollout. Our real-world findings complement existing immunogenicity and Phase 3 trial follow-up data of mRNA-1273 protection against SARS-CoV-2 variants, including Delta. High levels of neutralizing antibodies to Delta and other variants were elicited following 2-doses of mRNA-1273. 37 These antibodies were found to persist 6 months after vaccination, albeit at reduced levels compared with peak activity. Among Phase 3 trial participants, incidence rates of COVID-19 and severe COVID-19 during the months when Delta was predominant were lower among All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101/2021.09.29.21264199 doi: medRxiv preprint those who were vaccinated with mRNA-1273 more recently (median 8 months after first dose) compared to those vaccinated initially (median 13 months after first dose). 38 The findings of this study have implications for booster doses, which have been authorized in certain populations. Questions remain over the benefits of booster doses in different populations and optimal approaches for boosting immunity. Several studies have identified higher VE for mRNA-1273 after 1 and 2 doses compared to BNT162b2, 12, 39 suggesting different booster strategies could be appropriate depending on product. However, efforts to deploy booster doses must not replace efforts to reach unvaccinated individuals, who comprise most COVID-19 hospitalizations and deaths. Booster dose strategies must also prioritize global vaccine production and allocation. Our study had multiple strengths. We systematically collected positive SARS-CoV-2 specimens across KPSC care settings and sent specimens for WGS regardless of Ct value. Test-positive cases were matched to test-negative controls on demographic factors and calendar time, reducing secular confounding due to differences over time in transmission, vaccination rollout, and testing. We examined mRNA-1273 VE against multiple variants, including Delta and Mu. We also evaluated VE against Delta hospitalization. With data up to 6 months following receipt of two doses of mRNA-1273, we stratified analyses of duration of protection by variant type and age group. Our study also had several limitations. Although test-negative designs might reduce bias due to factors associated with care-seeking, 40 this design was generalizable to individuals who were tested and was therefore less generalizable to individuals with mild or no symptoms who did All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101/2021.09.29.21264199 doi: medRxiv preprint not seek testing. The detailed KPSC EHR enabled adjustment for comprehensive sociodemographic and clinical covariates, but there could still be residual confounding due to unmeasured factors associated with both testing and vaccination. Misclassification of case/control status could occur due to false positives or negatives, although sensitivity and specificity of PCR testing was high. Misclassification of vaccine exposure was also possible but unlikely due to comprehensive KPSC and external COVID-19 vaccination records. Sample size was limited in the subgroup aged ≥65 years for the analysis of VE against Delta infection by time since vaccination. In conclusion, this study found high VE of mRNA-1273 against infection due to SARS-CoV-2 variants, including Delta, adding to the limited literature specific for mRNA-1273. VE against hospitalization for Delta was also high. This study provides reassuring evidence of the effectiveness of 2 doses of mRNA-1273 in preventing infection and COVID-19 hospitalization due to variants including Delta. Moderate declines in VE were observed against Delta infection. Additional research is required to inform booster dose strategies over time. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. Individual-level data reported in this study are not publicly shared. Upon request, and subject to review, KPSC may provide the deidentified aggregate-level data that support the findings of this study. Deidentified data (including participant data as applicable) may be shared upon approval of an analysis proposal and a signed data access agreement. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. information, collected through our electronic health record systems, leads to findings that help us improve care for our members and can be shared with the larger community. All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101/2021.09.29.21264199 doi: medRxiv preprint Table 1 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101/2021.09.29.21264199 doi: medRxiv preprint Medical center area not shown. There were differences in the distribution of cases and controls across the medical center areas. Abbreviations: ASD, Absolute Standardized Difference; BMI, Body Mass Index; ED, Emergency Department; HIV/AIDS, Human Immunodeficiency Virus/Acquired Immunodeficiency Syndrome; N/A, Not Applicable All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101/2021.09.29.21264199 doi: medRxiv preprint 28 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101/2021.09.29.21264199 doi: medRxiv preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted October 1, 2021. ; https://doi.org/10.1101/2021.09.29.21264199 doi: medRxiv preprint Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Safety and Efficacy of the BNT162b2 mRNA Covid-19 United States Food and Drug Administration. Moderna COVID-19 Vaccine United States Food and Drug Administration Effectiveness of mRNA-BNT162b2, mRNA-1273, and ChAdOx1 nCoV-19 vaccines against COVID-19 in healthcare workers: an observational study using surveillance data Prevention of COVID-19 by mRNA-based vaccines within the general population of California Prevention and Attenuation of Covid-19 with the BNT162b2 and mRNA-1273 Vaccines SARS-CoV-2 Vaccine Effectiveness in a High Effectiveness of COVID-19 Vaccines in Preventing Hospitalization Among Adults Aged ≥65 Years -COVID-NET, 13 States mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar Effectiveness of BNT162b2 and mRNA-1273 covid-19 vaccines against symptomatic SARS-CoV-2 infection and severe covid-19 outcomes in Ontario, Canada: test negative design study Effectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant COVID vaccines slash viral spread -but Delta is an unknown Monitoring Incidence of COVID-19 Cases, Hospitalizations, and Deaths, by Vaccination Status -13 Outbreak of SARS-CoV-2 Infections Vaccine Breakthrough Infections, Associated with Large Public Gatherings -Barnstable County Effectiveness of COVID-19 mRNA Vaccines Against COVID-19-Associated Hospitalization -Five Veterans Affairs Medical Centers New COVID-19 Cases and Hospitalizations Among Adults, by Vaccination Status Effectiveness of COVID-19 Vaccines in Preventing SARS Infection Among Frontline Workers Before and During B.1.617.2 (Delta) Variant Predominance -Eight Effectiveness of Pfizer-BioNTech and Moderna Vaccines in Preventing SARS-CoV-2 Infection Among Nursing Home Residents Before and During Widespread Circulation of the SARS-CoV-2 B.1.617.2 (Delta) Variant -National Healthcare Safety Network Sociodemographic characteristics of members of a large, integrated health care system: comparison with US Census Bureau data Updated COVID-19 Vaccine Eligibility Guidelines. California Department of Public Health Reporting Doses Administered: California COVID-19 Vaccination Program Virological and serological kinetics of SARS-CoV-2 Delta variant vaccine-breakthrough infections: a multi-center cohort study Durability of mRNA-1273 vaccine-induced antibodies against SARS-CoV-2 variants Covid-19 in the Phase 3 Trial of mRNA-1273 During the Delta-variant Surge Comparative Effectiveness of Moderna Covid-19 Vaccine Effectiveness and the Test-Negative Design